Related Experiment Video
Updated: May 26, 2026
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Inflammatory markers in heart failure: hype or hope?
Pio Cialdella1, Daniela Pedicino, Massimo Gustapane
1Institute of Cardiology, Catholic University of Sacred Heart, Rome, Italy. piorules@hotmail.it
Journal of Cardiovascular Medicine (Hagerstown, Md.)
|December 14, 2011
Summary
Heart failure involves inflammation, with cytokines playing a key role in its progression. While not diagnostic, inflammatory biomarkers help assess prognosis, and current treatments may target inflammation.
Area of Science:
- Cardiology
- Immunology
- Biochemistry
Background:
- Heart failure is a global epidemic with a significant proinflammatory component.
- Elevated cytokine levels are implicated in the pathophysiology of heart failure, affecting left-ventricular remodeling and function.
Purpose of the Study:
- To review the role of inflammation and cytokines in heart failure.
- To evaluate inflammatory biomarkers for diagnosis, risk stratification, and guiding therapy.
- To discuss the efficacy of anti-inflammatory treatments and the impact of established therapies on cytokine expression.
Main Methods:
- Literature review of studies on heart failure, inflammation, and cytokine theory.
- Analysis of evidence regarding the diagnostic and prognostic utility of inflammatory biomarkers.
- Evaluation of clinical trial data for anti-inflammatory and established heart failure therapies.
Main Results:
- Inflammatory biomarkers are not currently supported for heart failure diagnosis but are validated for prognosis.
- Clinical trials of anti-inflammatory agents in heart failure have yielded controversial results.
- Established heart failure treatments (e.g., beta-blockers, RAAS inhibitors) may modulate cytokine expression.
Conclusions:
- The relationship between heart failure and inflammation remains an area for further exploration.
- While direct anti-inflammatory therapies show mixed results, existing treatments may offer benefits through cytokine modulation.
- Future research should focus on the intricate roles of inflammation in guiding heart failure management.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...